Integrated Advisors Network LLC Trims Position in IQVIA Holdings Inc. (NYSE:IQV)

Integrated Advisors Network LLC trimmed its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 39.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,189 shares of the medical research company's stock after selling 4,746 shares during the quarter. Integrated Advisors Network LLC's holdings in IQVIA were worth $1,267,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IQV. Howard Capital Management Inc. raised its stake in IQVIA by 4.9% during the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock worth $225,000 after buying an additional 54 shares during the period. Continuum Advisory LLC grew its holdings in shares of IQVIA by 3.7% in the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock valued at $354,000 after acquiring an additional 64 shares in the last quarter. ST Germain D J Co. Inc. raised its stake in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after purchasing an additional 76 shares in the last quarter. New York Life Investment Management LLC grew its holdings in IQVIA by 0.4% during the fourth quarter. New York Life Investment Management LLC now owns 23,086 shares of the medical research company's stock worth $4,537,000 after purchasing an additional 81 shares during the period. Finally, Zions Bancorporation N.A. lifted its holdings in IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on IQV shares. HSBC downgraded shares of IQVIA from a "buy" rating to a "hold" rating and cut their price objective for the stock from $260.00 to $160.00 in a research report on Friday, April 25th. Truist Financial dropped their price target on IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a report on Thursday, April 10th. UBS Group decreased their price objective on IQVIA from $255.00 to $185.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Citigroup reissued a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Finally, Robert W. Baird decreased their price target on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Eight research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, IQVIA presently has an average rating of "Moderate Buy" and a consensus price target of $226.32.

IQVIA Stock Down 1.6%

IQVIA stock traded down $2.48 during mid-day trading on Friday, reaching $156.65. The stock had a trading volume of 1,473,864 shares, compared to its average volume of 1,616,080. The stock's 50-day simple moving average is $147.33 and its 200-day simple moving average is $177.98. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a market capitalization of $27.10 billion, a PE ratio of 20.89, a price-to-earnings-growth ratio of 1.99 and a beta of 1.28.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The firm had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. During the same period last year, the company earned $2.54 earnings per share. The business's revenue was up 2.5% on a year-over-year basis. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.